AIDS Research and Human Retroviruses · 2004 · 29 citations · 50 references
MedicineNeurologyNeuroscienceCognitive NeuroscienceDementiaNeuropsychiatryAntiretroviral TherapyCognitive ImpairmentCognitive SymptomsDementia PreventionDementia TreatmentClinical Event-related PotentialsDementia-related Cognitive SymptomsHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyHiv-associated Cognitive ImpairmentHiv-associated DementiaIncomplete PenetranceLongitudinal Correlation Study
The impact of the cerebrospinal fluid (CSF) penetrance properties of different highly active antiretroviral therapy (HAART) regimes on cognitive processing in AIDS dementia is still undetermined. We therefore designed a retrospective cross-sectional and prospective longitudinal analysis of event-related potentials in HIV-infected patients with different combinations of HAART or without antiretroviral treatment. A total of 353 consecutive patients without secondary CNS manifestation of HIV infection were enrolled in the cross-sectional study and 135 consecutive patients without secondary CNS manifestations of HIV infection were enrolled in the longitudinal study. HAART in different combinations (n = 306) or no antiretroviral treatment (n = 47) was given for at least 6 months in the retrospective cross-sectional study. HAART in different combinations (n = 110) or no antiretroviral treatment (n = 25) was given for 1 year in the prospective longitudinal study. We evaluated the latency and amplitude of the P3 component of visually evoked event-related potentials and mean choice reaction time as measures of cognitive processing. Patients receiving HAART had decreased P3 latencies as compared to those patients not receiving HAART but P3 latency and P3 amplitude were not correlated with the amount of CSF penetrance of the different HAART combinations in either statistical analysis. However, mean choice reaction time was significantly correlated with the amount of CSF penetrance. In HIV-infected patients, the CSF penetrance properties of HAART do not have any significant influence on cognitive processing as measured by event-related potentials.
50
HIV-associated neurologic disease incidence changes:
Ned Sacktor, Robert H. Lyles, Richard L. Skolasky et al. · Neurology · 2001 · 593 citations
HIV-associated cognitive impairment before and after the advent of combination therapy
Ned Sacktor, Michael McDermott, Karen Marder et al. · Journal of NeuroVirology · 2002 · 592 citations · Full text
Medicine, Neurology, Pharmacotherapy +14
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
Gregory J. Dore, Patricia Correll, Yueming Li et al. · AIDS · 1999 · 420 citations
Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy
E.A. Childs, Robert H. Lyles, Ola A. Selnes et al. · Neurology · 1999 · 307 citations
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.
Peter Portegies, Jan de Gans, Joep M. A. Lange et al. · BMJ · 1989 · 239 citations · Full text